Cathy Pelican
Family · Neptune, NJNPI 1194054379
Payments from drug & device makers
Across 113 payments — averaging $24.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$921
- AstraZeneca$408
- Cvrx, Inc.$223
- Pfizer$208
- Merck$180
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$156
- plus $669 from 15 others
What the payments were for
- Food & beverage$2,54992%
- Education$2158%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 23 | $921 |
| AstraZeneca | 21 | $408 |
| Cvrx, Inc. | 5 | $223 |
| Pfizer | 9 | $208 |
| Merck | 11 | $180 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $156 |
| E.r. Squibb & Sons, L.L.C. | 9 | $145 |
| Daiichi Sankyo Inc. | 5 | $98 |
| Boehringer Ingelheim | 6 | $88 |
| Novartis | 4 | $75 |
| Johnson & Johnson | 1 | $44 |
| Abiomed | 1 | $42 |
| Lexicon Pharmaceuticals, Inc. | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 2 | $31 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Sobi, Inc | 1 | $16 |
| Impulse Dynamics (USA) Inc. | 1 | $16 |
| Akcea Therapeutics, Inc. | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $14 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,764 in reported general payments places this provider in the 90th percentile of 2,692 family providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 70 | $79,151 |
| JardianceEmpagliflozin | 18 | $18,749 |
| FarxigaDapagliflozin Propanediol | 11 | $14,125 |
| Bumetanide | 22 | $1,130 |
| Metoprolol Succinate | 28 | $750 |
| Sildenafil Citrate | 18 | $727 |
| Carvedilol | 27 | $428 |
| Potassium Chloride | 21 | $427 |
| Warfarin Sodium | 28 | $329 |
| Atorvastatin Calcium | 14 | $225 |
| Spironolactone | 28 | $162 |
| Pantoprazole Sodium | 12 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $75 | $79,15170 claims |
| Boehringer IngelheimJardiance | $88 | $18,74918 claims |
| AstraZenecaFarxiga | $408 | $14,12511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,692 family providers in New Jersey.
Other family in Neptune
- Timothy KellyNeptune$10K
- Melissa JohnsonNeptune$9K
- Svetlana ChehetNeptune$9K
- Jennifer DemaioMorristown$412K
- Kara TrlicaCranbury$186K
- Nicole BauerParamus$161K
- Angie GarciaWest New York$161K
- China BattistaWall Township$142K
- Nancy EisenbergerVoorhees$82K
- Jennifer AbitabiloGlen Ridge$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.